Medicare Proposes To Cover J&J’s Natrecor For Labeled Indication Only
Executive Summary
The Centers for Medicare & Medicaid Services is proposing to restrict Medicare coverage of Johnson & Johnson/Scios' Natrecor to its labeled indication for acutely decompensated heart failure, rather than provide wider coverage for the drug under a "coverage with evidence development" program
You may also be interested in...
Medicare And Alzheimer’s Drugs: Recent NCDs Mainly Omit Research Requirement, Biogen Notes
Biogen suggests potential precedents in past coverage decisions for upcoming Medicare determination on Aduhelm and other amyloid-directed monoclonal antibodies during earnings call.
CMS Natrecor NCD
Medicare contractors may opt to cover J&J/Scios' Natrecor for some off-label uses despite a March 2 CMS national coverage decision against using nesiritide for chronic heart failure. The decision "does not change contractor discretion to cover other off-label uses of nesiritide" or affect coverage for the labeled indication of acutely decompensated heart failure, CMS said. The agency had expressed concern about the drug's potential for increased mortality rates and renal dysfunction. The NCD review found inconsistent data on use of Natrecor for chronic heart failure (1"The Pink Sheet" Dec. 12, 2005, p. 12)...
CMS Natrecor NCD
Medicare contractors may opt to cover J&J/Scios' Natrecor for some off-label uses despite a March 2 CMS national coverage decision against using nesiritide for chronic heart failure. The decision "does not change contractor discretion to cover other off-label uses of nesiritide" or affect coverage for the labeled indication of acutely decompensated heart failure, CMS said. The agency had expressed concern about the drug's potential for increased mortality rates and renal dysfunction. The NCD review found inconsistent data on use of Natrecor for chronic heart failure (1"The Pink Sheet" Dec. 12, 2005, p. 12)...